Filtered By:
Condition: Hypertension
Management: Insurance

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 444 results found since Jan 2013.

Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA 2 DS 2 -VASc Score (Beyond Sex) Receive Oral Anticoagulation?
ConclusionsNot all risk factors in CHA2DS2-VASc score carry an equal risk, with age 65 to 74 years associated with the highest stroke rate. Oral anticoagulation should be considered for AF patients with 1 additional stroke risk factor given their high risk of ischemic stroke.
Source: Journal of the American College of Cardiology - February 16, 2015 Category: Cardiology Source Type: research

PPAR agonists for the treatment of cardiovascular disease in patients with Diabetes
Conclusions: According to this study, Pioglitazone treatment in type 2 diabetes patients and hypersensitive Ischemic stroke patients is linked to minor ischemic stroke which is recurrent in Asian people. Pioglitazone and the telmisartan treatment have an increasing pleiotropic effect related to the higher PPAR- gamma effects. Further research needs to be conducted with the PPAR mechanism ' s details to confirm the PPAR effect on Ischemic stroke treatment. [Ethiop. J. Health Dev. 2021; 35(3): 249-257]Keywords: PPAR agonist, Dyslipidaemia, Thiazolidinediones, Type 2 diabetes, Pioglitazone, PPAR-alpha, PPAR-gamma, Insulin resistance, Alecardio.
Source: Ethiopian Journal of Health Development - November 25, 2021 Category: African Health Authors: Zheng Xia, Guo Lixia, Zhang Zhijun Source Type: research

AF News
This article is protected by copyright. All rights reserved
Source: Journal of Cardiovascular Electrophysiology - April 2, 2015 Category: Cardiology Authors: Tze‐Fan Chao, Li‐Wei Lo, Shih‐Ann Chen Tags: AF News Source Type: research

Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)? Arrhythmia and Electrophysiology
ConclusionsFor atrial fibrillation patients aged 20 to 49 years with 1 risk factor in addition to sex, non–vitamin K antagonist OACs should be considered for stroke prevention to minimize the risk of a potentially fatal or disabling event.
Source: JAHA:Journal of the American Heart Association - October 3, 2016 Category: Cardiology Authors: Hung, Y., Chao, T.-F., Liu, C.-J., Tuan, T.-C., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Liao, J.-N., Chung, F.-P., Lin, W.-Y., Lin, W.-S., Cheng, S.-M., Chen, T.-J., Lip, G. Y. H., Chen, S.-A. Tags: Atrial Fibrillation Original Research Source Type: research

Effects of acupuncture on cardiovascular risks in patients with hypertension: a Korean cohort study.
CONCLUSION: This observational study with long-term follow-up extends the evidence base in support of the effectiveness of acupuncture for the management of hypertension and potentially reduce the burden of cardiovascular disease. PMID: 32567334 [PubMed - as supplied by publisher]
Source: Acupuncture in Medicine - June 19, 2020 Category: Complementary Medicine Authors: Jung H, Yeo S, Lim S Tags: Acupunct Med Source Type: research

Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population.
CONCLUSIONS: Bleeding incidence among patients with NVAF in a real-world setting was high and increased with greater stroke and bleeding risk scores. Health care costs for patients with major bleeding events were elevated. All rights reserved. PMID: 24075151 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 25, 2013 Category: Drugs & Pharmacology Authors: Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J Tags: Clin Ther Source Type: research

Impact of CHA2DS2VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multipayer Analysis.
Abstract PURPOSE: The purpose of this study is to report on the effect of using CHA2DS2VASc (congestive heart failure, hypertension, age ≥75 years [doubled], type 1 or type 2 diabetes mellitus, stroke or transient ischemic attack or thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75 years, sex category [female]) rather than CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke) to determine candidacy for anticoagulant prophylaxis in insured patients with atrial fibrillation (AF). MET...
Source: Clinical Therapeutics - September 22, 2016 Category: Drugs & Pharmacology Authors: Patel AA, Nelson WW, Schein J Tags: Clin Ther Source Type: research

Effect of Radiofrequency Catheter Ablation for Atrial Fibrillation on Morbidity and Mortality: A Nationwide Cohort Study and Propensity Score Analysis Original Articles
Conclusions— RFA did not reduce mortality or hospitalization for HF during the immediate 3.5-year follow-up. Although a beneficial effect on stroke prevention associated with RFA was suggested, residual confounding attributable to unmeasured factors remains a concern.
Source: Circulation: Arrhythmia and Electrophysiology - February 18, 2014 Category: Cardiology Authors: Chang, C.-H., Lin, J.-W., Chiu, F.-C., Caffrey, J. L., Wu, L.-C., Lai, M.-S. Tags: Ablation/ICD/surgery Original Articles Source Type: research

The Patients We Do Not See
This article was originally published on The Conversation. Read the original article. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - April 28, 2017 Category: Consumer Health News Source Type: news

Sleep Duration Is Associated With Subclinical Carotid Plaque Burden
CONCLUSIONS: The association between long sleep and subclinical carotid atherosclerosis may explain prior associations between long sleep and stroke.PMID:37470161 | DOI:10.1161/STROKEAHA.122.041967
Source: Atherosclerosis - July 20, 2023 Category: Cardiology Authors: Christian Agudelo Alberto R Ramos Hannah Gardener Ken Cheung Mitchell S V Elkind Ralph L Sacco Tatjana Rundek Source Type: research

Abstract 144: Cost of Cardiovascular Disease Episodes among Patients with Hypertension Session Title: Poster Session I
Conclusions: Cost estimates of CVD episodes among hypertensive patients are consistent with results from the scarce literature in this area. Moreover, our study finds evidence of increased medical resource utilization weeks before the recording of the CVD episode. Omitting these pre-event costs leads to an underestimate of the true costs of CVD.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Arrieta, A., Qiao, N., Woods, J. R., Jay, S. J., Veledar, E., Nasir, K. Tags: Session Title: Poster Session I Source Type: research

Long-term outcomes of lercanidipine versus other calcium channel blockers in newly-diagnosed hypertension: a nationwide cohort study.
CONCLUSION: In newly diagnosed patients with hypertension, lercanidipine was superior than nifedipine in the six-year period when the analyzed endpoint was stroke. PMID: 28300435 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Nearly Half of Americans Have Some Form of Heart Disease
About 48% of adults in the U.S. have some type of heart or blood vessel disease, according to a new annual report from the American Heart Association published in the journal Circulation. The finding, based on data collected from 2016, means that almost half of Americans have had a heart attack, stroke, angina, abnormal heart rhythms, or narrowing of the arteries. The new report also shows that deaths from heart disease, after declining in recent years, rose from 2015 to 2016, from 836,546 to 840,678. Dr. Mariell Jessup, chief science and medical officer at the American Heart Association, said much of the increase in the p...
Source: TIME: Health - January 31, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Heart Disease Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news